Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924664 · ClinicalTrials.gov registry record · Phase 2
Long Term Safety Study of Tanezumab in Chronic Low Back Pain
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 849
- Enrollment target
NCT00924664 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 849 participants.
The verdict
NCT00924664, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 849 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of tanezumab for chronic low back pain. Patients who were randomized and treated with study medication in a previous chronic low back pain "parent" study will be eligible to enroll in this safety extension study at the Preferred Rollover Time Point visit or at the Early Termination visit of the parent study upon discontinuation due to lack of efficacy.
Interventions
- BIOLOGICAL Tanezumab 20 mg
- BIOLOGICAL Tanezumab 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 849 participants |
| Start Date | 2009-08-20 |
| Est. Completion | 2011-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924664
The ClinicalTrials.gov registry entry for NCT00924664 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 849 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tanezumab 20 mg is the first listed.
NCT00924664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924664 about?
NCT00924664 is a clinical study titled "Long Term Safety Study of Tanezumab in Chronic Low Back Pain". The purpose of this study is to investigate the safety and efficacy of tanezumab for chronic low back pain. Patients who were randomized and treated with study medication in a previous chronic low back pain "parent" study will be eligible to enroll in this safety extension study at the Preferred Rol...
What is the current status of trial NCT00924664?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 849 participants. The study started on 2009-08-20. Estimated completion is 2011-06-22.
What interventions are being tested in trial NCT00924664?
The interventions under investigation include: Tanezumab 20 mg (BIOLOGICAL), Tanezumab 10 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00924664?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.